Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-02-10

Clinical Trial Update: BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 trial of BAY 43-9006 (sorafenib) in patients with previously untreated non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BAY 43-9006 (sorafenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Cancer | Phase 1 | Status: COMPLETED